<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03202511</url>
  </required_header>
  <id_info>
    <org_study_id>1705315090</org_study_id>
    <nct_id>NCT03202511</nct_id>
  </id_info>
  <brief_title>Assessment of a New &quot;Boosting&quot; Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers</brief_title>
  <official_title>Assessment of a New &quot;Boosting&quot; Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a randomized, open-label, cross-over clinical pharmacokinetic trial to&#xD;
      investigate a strategy for probenecid &quot;boosting&quot; in the setting of tenofovir disoproxil&#xD;
      fumarate (TDF)/emtricitabine (FTC) for HIV pre-exposure prophylaxis (PrEP). The study will be&#xD;
      conducted at the Indiana University Clinical Research Center. All samples will be processed&#xD;
      and the amount of tenofovir/FTC in plasma, blood, and urine, and tenofovir diphosphate and&#xD;
      emtricitabine in peripheral blood mononuclear cells will be determined using validated&#xD;
      analytical methods developed by the investigators at the University of Colorado. Probenecid&#xD;
      plasma and urine concentrations will also be measured using an in-house assay. Following&#xD;
      completion of the study, the secondary aim will be accomplished via analysis of selected&#xD;
      samples collected at baseline and following treatment. Those selected samples will be&#xD;
      assessed for urinary markers of proximal tubulopathy (urine total protein, albumin,&#xD;
      creatinine, phosphorus, retinol binding protein, and beta-2-microglobulin) and serum alkaline&#xD;
      phosphatase, osteocalcin, procollagen type 1 N propeptide, cystatin C, and creatinine to&#xD;
      determine if the probenecid boosting strategy does indeed lead to less potential renal and&#xD;
      bone toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2017</start_date>
  <completion_date type="Actual">July 2, 2018</completion_date>
  <primary_completion_date type="Actual">July 2, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomly allocated to enter the study in either the control or treatment arm using a blocked design to ensure equal numbers of subjects in each sequence group (n=8, control to treatment; n=8, treatment to control). Following a washout period of at least 6 weeks, each individual will crossover to the next study phase. The randomization table will be constructed prior to subject enrollment by the Principal Investigator using the Statistical Analysis Software (SAS®) randomization procedure. In the event that an individual is withdrawn from the study, an alternate participant will replace that individual using an identical study sequence to maintain the block design. A total of 16 subjects will be initially enrolled in an effort to ensure that at least 14 subjects complete the entire study. If needed, additional subjects will be screened and enrolled until the target enrollment of n=14 subjects have completed the entire study.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This will be an open-label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma TFV AUC0-INF GMR</measure>
    <time_frame>The first 72 hours of each phase.</time_frame>
    <description>The geometric mean ratio (GMR) of the plasma TFV area under the curve (AUC) comparing the test phase (T) to control phase (C) was assessed. PK samples were collected from 0 to 72 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PBMC TFV-DP AUC GMR</measure>
    <time_frame>The first 72 hours of each phase.</time_frame>
    <description>The geometric mean ratio (GMR) of the PBMC TFV-DP area under the curve (AUC) comparing the test phase (T) to control phase (C) was assessed. PK samples were collected from 0 to 72 hours post-dose.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Pre-Exposure Prophylaxis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) on day 1 (2 tablets) followed by 300/200 mg (1 tablet) doses on days 2 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (2 tablets) along with a 2 gram oral probenecid (PRO) dose (4 tablets, 500 mg each) on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probenecid Oral Tablet</intervention_name>
    <description>Included in arm/group descriptions.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate/Emtricitabine</intervention_name>
    <description>Included in arm/group descriptions.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>TDF/FTC, Truvada</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 to 55 years old healthy (as decided from a pre-enrollment screening session&#xD;
             described above) male participants within 32% of their ideal body weight.&#xD;
&#xD;
          2. Individuals who agree to refrain from taking any prescriptions medications,&#xD;
             over-the-counter medications (including salicylates/aspirin), hormonal agents, and&#xD;
             herbal, dietary, and alternative supplements that may interact with the metabolism of&#xD;
             those study drugs at least 2 weeks prior to the start of the study and until study&#xD;
             completion.&#xD;
&#xD;
          3. Nonsmoker or individuals willing to refrain from smoking or use of tobacco or&#xD;
             marijuana for at least one month prior to and until the completion of the study (the&#xD;
             entire study lasts for approximately 49 days).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Are underweight (weigh less than 52 kg or 114 lb) or overweight [body mass index&#xD;
             (BMI) greater than 32].&#xD;
&#xD;
             2. Females will be excluded to reduce study variability for this first proof of&#xD;
             concept study.&#xD;
&#xD;
             3. Have insufficient renal function (estimated Creatinine Clearance ≤ 90 mL/min).&#xD;
&#xD;
             4. Have history of current alcohol or drug abuse (more than 4 alcoholic drinks per day&#xD;
             on a regular basis).&#xD;
&#xD;
             5. Have history of intolerance, allergic reactions (e.g. rash) or other forms of&#xD;
             hypersensitivities to any of the study medications (tenofovir disoproxil fumarate/&#xD;
             emtricitabine, probenecid).&#xD;
&#xD;
             6. Have taken TDF or FTC as part of pre-exposure prophylaxis within the past 6 weeks.&#xD;
&#xD;
             7. Any current major illness or chronic illness such as (but not limited to) kidney&#xD;
             disease, hepatic disease, diabetes mellitus, gout, hypertension, coronary artery&#xD;
             disease, chronic obstructive pulmonary disease, cancer, chronic active hepatitis B&#xD;
             virus (HBV) infection, or HIV.&#xD;
&#xD;
             8. History of anemia or any other significant hematologic disorder. 9. Have history or&#xD;
             current gastrointestinal disorders such as persistent diarrhea or malabsorption that&#xD;
             would interfere with the absorption of orally administered drugs.&#xD;
&#xD;
             10. Have a serious infection within the last week before study enrollment. 11. Have&#xD;
             donated blood within the past two months. 12. Have blood results that do not fall in a&#xD;
             healthy range (e.g., blood hemoglobin less than 12.0 mg/dl).&#xD;
&#xD;
             13. Are taking on regular basis substances that may interfere with the metabolism&#xD;
             (breakdown) of study medications by the body, including prescription medications,&#xD;
             over-the-counter, herbal or dietary supplements, alternative medications, or hormonal&#xD;
             agents (i.e. oral contraceptives, intra-uterine device with hormones).&#xD;
&#xD;
             14. Have a life style that places subjects at a higher risk for contracting HIV during&#xD;
             the study period (e.g. active illicit drug use, excessive alcohol drinking, sexually&#xD;
             transmitted infection (including gonorrhea, chlamydia, syphilis, herpes, human&#xD;
             papilloma virus) within the past one year, or having more than one sexual partner in&#xD;
             the past 6 months).&#xD;
&#xD;
             15. Positive HIV antibody test. 16. Positive HBV surface antigen test. 17. Have&#xD;
             participation in a research study or use of an investigational drug in the last one&#xD;
             month.&#xD;
&#xD;
             18. Are employed or are student under supervision of any of the investigators of this&#xD;
             study.&#xD;
&#xD;
             19. Cannot state a good understanding of this study including risks and requirements;&#xD;
             are unable to follow the rules of this study.&#xD;
&#xD;
             20. Cannot commit the time requested for this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only male healthy volunteers will be enrolled.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandon T Gufford, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana Unversity School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Clinical Research Center at University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <results_first_submitted>April 24, 2019</results_first_submitted>
  <results_first_submitted_qc>April 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2021</results_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Zeruesenay Desta</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Probenecid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We do not plan to share IPD with other researchers.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03202511/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment TDF/FTC+PRO Dose First, Then Control TDF/FTC</title>
          <description>Participants received the treatment phase of 600/400 mg oral TDF/FTC along with a 2 gram oral PRO on day 1, 2-week washout, then the control phase of 600/400 mg oral TDF/FTC on day 1 followed by 300/200 mg oral TDF/FTC on days 2 and 3.</description>
        </group>
        <group group_id="P2">
          <title>Control TDF/FTC First, Then Treatment TDF/FTC+PRO Dose</title>
          <description>Participants received the control phase of 600/400 mg oral TDF/FTC on day 1 followed by 300/200 mg oral TDF/FTC on days 2 and 3, 2-week washout, then the treatment phase of 600/400 mg oral TDF/FTC along with a 2 gram oral PRO on day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All participants received control and/or treatment phase&#xD;
The control phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) on day 1 (2 tablets) followed by 300/200 mg (1 tablet) doses on days 2 and 3.&#xD;
The treatment phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (2 tablets) along with a 2 gram oral probenecid (PRO) dose (4 tablets, 500 mg each) on day 1.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" lower_limit="18" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma TFV AUC0-INF GMR</title>
        <description>The geometric mean ratio (GMR) of the plasma TFV area under the curve (AUC) comparing the test phase (T) to control phase (C) was assessed. PK samples were collected from 0 to 72 hours post-dose.</description>
        <time_frame>The first 72 hours of each phase.</time_frame>
        <population>Primary result was performed for geometric mean ratio of treatment phase to control phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Phase</title>
            <description>The treatment phase will consist of subjects taking 600/400 mg oral TDF/FTC along with a 2 gram oral PRO dose on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Control Phase</title>
            <description>The control phase will consist of subjects taking 600/400 mg oral TDF/FTC on day 1 followed by 300/200 mg TDF/FTC on days 2 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma TFV AUC0-INF GMR</title>
          <description>The geometric mean ratio (GMR) of the plasma TFV area under the curve (AUC) comparing the test phase (T) to control phase (C) was assessed. PK samples were collected from 0 to 72 hours post-dose.</description>
          <population>Primary result was performed for geometric mean ratio of treatment phase to control phase.</population>
          <units>ng*h/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.75" lower_limit="8.66" upper_limit="8.84"/>
                    <measurement group_id="O2" value="8.27" lower_limit="8.18" upper_limit="8.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>0.8 to 1.25 equivalence margin was used.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.61</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.47</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PBMC TFV-DP AUC GMR</title>
        <description>The geometric mean ratio (GMR) of the PBMC TFV-DP area under the curve (AUC) comparing the test phase (T) to control phase (C) was assessed. PK samples were collected from 0 to 72 hours post-dose.</description>
        <time_frame>The first 72 hours of each phase.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Phase</title>
            <description>The treatment phase will consist of subjects taking 600/400 mg oral TDF/FTC along with a 2 gram oral PRO dose on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Control Phase</title>
            <description>The control phase will consist of subjects taking 600/400 mg oral TDF/FTC on day 1 followed by 300/200 mg TDF/FTC on days 2 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>PBMC TFV-DP AUC GMR</title>
          <description>The geometric mean ratio (GMR) of the PBMC TFV-DP area under the curve (AUC) comparing the test phase (T) to control phase (C) was assessed. PK samples were collected from 0 to 72 hours post-dose.</description>
          <units>fmol*h/10^6cells</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.12" lower_limit="6.96" upper_limit="7.29"/>
                    <measurement group_id="O2" value="7.38" lower_limit="7.22" upper_limit="7.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>80 to 125% equivalence margin was used.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>77.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>61.4</ci_lower_limit>
            <ci_upper_limit>97.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over 1 year during study conduction.</time_frame>
      <desc>All adverse events reported from participant were included and graded for severity by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). Adverse events were reviewed per patient by treatment and was not separated individually.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control Phase</title>
          <description>The control phase consisted of subjects taking 600/400 mg oral TDF/FTC on day 1 followed by 300/200 mg TDF/FTC on days 2 and 3.</description>
        </group>
        <group group_id="E2">
          <title>Treatment Phase</title>
          <description>The treatment phase consisted of subjects taking 600/400 mg oral TDF/FTC followed by 2 gram oral PRO on day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Nose bleed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea, vomiting, or GERD</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache or loss of appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Zeruesenay Desta</name_or_title>
      <organization>Division of Clinical Pharmacology, School of Medicine, Indiana University</organization>
      <phone>317-274-2823</phone>
      <email>zdesta@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

